Together, our findings support the idea that early interventions aimed at reducing inflammation are more likely to be beneficial for patients at risk of progressing to severe COVID-19 than attempts to inhibit cytokine storm later in the disease course, given that early IFN responses were found to provoke better controlled immune responses and outcomes in our virtual cohort. The gene discussed is IFNA1; the disease is COVID-19.